Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Dewit

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Acta Gastro-Enterologica Belgica|April 2, 2020
Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)C Reenaers, A Cremer, O Dewit, et al.
Journal of Crohn'S & Colitis|March 9, 2012
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitisM De Vos, O Dewit, G D'Haens, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)D Franchimont, M Ferrante, E Louis, et al.
Alimentary Pharmacology & Therapeutics|March 5, 2013
Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitisB Flourié, H Hagège, G Tucat, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumabH Peeters, E Louis, F Baert, et al.
Journal of Crohn'S & Colitis|February 26, 2022
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort StudyC Cottron, X Treton, R Altwegg, et al.
Clinical Biochemistry|July 5, 2011
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patientsO Dewit, T Moreels, F Baert, et al.
The American Journal of Gastroenterology|March 10, 2011
Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitisS Leblanc, M Allez, P Seksik, et al.
Journal of Crohn'S & Colitis|September 10, 2015
Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled TrialA Senéjoux, L Siproudhis, L Abramowitz, et al.
Acta Gastro-Enterologica Belgica|February 14, 2013
Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's diseaseE De Greef, I Hoffman, G D'Haens, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Acta Gastro-Enterologica Belgica|April 2, 2020
Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)C Reenaers, A Cremer, O Dewit, et al.
Journal of Crohn'S & Colitis|March 9, 2012
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitisM De Vos, O Dewit, G D'Haens, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)D Franchimont, M Ferrante, E Louis, et al.
Alimentary Pharmacology & Therapeutics|March 5, 2013
Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitisB Flourié, H Hagège, G Tucat, et al.
Acta Gastro-Enterologica Belgica|March 22, 2018
Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumabH Peeters, E Louis, F Baert, et al.
Journal of Crohn'S & Colitis|February 26, 2022
How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort StudyC Cottron, X Treton, R Altwegg, et al.
Clinical Biochemistry|July 5, 2011
Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patientsO Dewit, T Moreels, F Baert, et al.
The American Journal of Gastroenterology|March 10, 2011
Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitisS Leblanc, M Allez, P Seksik, et al.
Journal of Crohn'S & Colitis|September 10, 2015
Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled TrialA Senéjoux, L Siproudhis, L Abramowitz, et al.
Acta Gastro-Enterologica Belgica|February 14, 2013
Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's diseaseE De Greef, I Hoffman, G D'Haens, et al.
Pageof 5